Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
about
Therapeutic Implications of Targeting AKT Signaling in MelanomaTargeting RTK Signaling Pathways in CancerCancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domainNext generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panelAKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung CancerTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Absence of AKT1 mutations in glioblastoma.High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.Identifying subtype-specific associations between gene expression and DNA methylation profiles in breast cancerThe class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic interventionMultiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinomaKnock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.Regulation of Akt signaling activation by ubiquitination.Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinomaClinical detection and categorization of uncommon and concomitant mutations involving BRAF.K63-linked ubiquitination in kinase activation and cancer.AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.Mutant AKT1-E17K is oncogenic in lung epithelial cellsThe transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.A novel AKT3 mutation in melanoma tumours and cell linesFrequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.Systematic morphological profiling of human gene and allele function via Cell Painting.Potential role of PI3K inhibitors in the treatment of breast cancer.Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.Molecular oncology of lung cancer.Targeting the PI3K signaling pathway in cancer therapy.Targeting the PI3K pathway for cancer therapy.EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.AKT Inhibition in Solid Tumors With AKT1 Mutations.AKT in cancer: new molecular insights and advances in drug development.Genetic landscape of meningioma.Targeting protein kinase-b3 (akt3) signaling in melanoma.
P2860
Q24631438-047F02F7-69F1-432B-ACAA-D17FA4A3AF08Q26781278-CDA73E4B-E1C1-4949-9579-FB5262F12BC3Q28533515-C7E1FAC8-72CB-4ADA-97BD-4E03CECD86E4Q28541288-3A740271-998F-416A-BCF0-B1C09C41FA8DQ28550038-C3F2384A-EFEF-429C-9F69-AAA15BA06D3AQ28550300-D6879EEB-C99E-4A40-83D4-838DFB4AA520Q30439629-E7CE5DEB-1F6E-4B59-9EFC-69AE244F5DE4Q33515565-E86D9AEA-5276-482F-844F-2EA25D2B0200Q33610437-3AFF2311-74A4-49A6-98A1-2B922E4D7D6FQ33637346-5586AAD7-8E1F-49E2-88CB-A0623F2F32B4Q33771056-6A4456C5-B3D5-4962-9BC2-0E67B99FF21CQ34286759-A09549D3-A848-4928-835F-E1AA7A99908AQ34586019-9FE0F721-8258-4119-B336-28F2CD88D473Q34592027-E18E0633-40EE-40B6-AE87-8DC91EA61F53Q34616536-39B4B40D-273B-474D-9ACB-321E9AE1FCFEQ34799443-075F226A-96B9-4E77-9F3B-DB15FF3C58AEQ35691075-FFE36A48-2F2F-43FB-9735-2A5F9C6B9A15Q35735954-C5677A37-DFF7-4B26-A4FE-443225D3B122Q35820044-84E8D504-5B49-42E4-8DC0-F89FF884ED2CQ35971438-AEA779B9-2475-4E8E-8570-6B48F7FBC83DQ36101969-640BFAF3-8213-40CF-8F34-04C3ECFD0E6DQ36545440-7492E33E-7DBE-4DC6-9BD5-38ACB679CB7FQ36858031-84DF38FA-BE3D-4C91-A1AB-BCFAACC5B336Q36939659-98476B99-4EA8-419F-8559-C551F0C68521Q36944047-B56FED82-CF39-45BD-877A-566B607DF920Q37131339-6B7BCB2C-024E-40FE-8081-12E2EE6FDAE2Q37269747-4B4CB6C3-BDC0-4E5C-BE8B-943F7CA989ECQ37692104-766AFD7F-740B-4409-82A1-670D62BFDD05Q37745645-6A629FB8-CF18-4157-960A-FD9BFFE6E18AQ37783617-9655B6FD-6E23-4016-9622-CCEFBDBB9571Q37872655-79505E7A-6F70-4719-874E-308ED42ABF5CQ37919395-B6B55E87-1A92-4F46-8000-6F623AA0371EQ37975242-1EEE85E8-0329-4821-8E3D-4212B21A2B9AQ38019609-F270481C-C97D-4D0E-98F1-7C20FF14B84DQ38034817-53EAE595-8413-4496-B916-818EA81F7098Q38242086-ED6B3382-0B70-47A0-9702-A23CE7EC94FDQ38794254-9A80E479-D43E-48F5-B7F4-6AC4D000D812Q38846044-44CEA515-AAA6-4F54-92CC-A2881E8B9F6BQ38953562-ED01C606-AC0B-409F-86B8-22D9FC957A46Q39074281-21059371-822B-4195-8918-B0E5DEC5F522
P2860
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@ast
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@en
type
label
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@ast
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@en
prefLabel
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@ast
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@en
P2093
P2860
P356
P1476
Mutational analysis of oncogen ...... d cancers and acute leukaemias
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604212
P407
P577
2008-04-08T00:00:00Z
P5875
P6179
1049947560